More indirect targeting of the potently transforming heterodimeric complex of ERBB3 with ERBB2 (with anti-ERBB2 drugs or compounds such as bispecific ERBB3/ERBB2 antibodies) provides another route for activity against ERBB3-driven cancer. The gene discussed is ERBB3; the disease is cancer.